Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis
Status:
Recruiting
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
Glucocorticoids remain to be among the most important and most frequently used
anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic
(and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially
if higher dosages have to be given over longer periods of time. The available data describing
frequency and severity of these adverse effects are fragmentary. This statement is especially
true for glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory
rheumatic diseases or (in part) psoriasis(arthritis). The state of knowledge and scientific
data, being sparse, is partly conflicting and often derived from over-aged projects or
studies. Therefore, there are urgent needs to work on various current questions
systematically and at the highest scientific level possible. In order to address these needs,
we aim at collecting and analyzing disease- and bone-related data from patients with chronic
inflammatory rheumatic diseases or psoriasis and therapy with glucocorticoids, and to build a
respective GIOP-Databank. Patients will attend for diagnostics, and where necessary therapy
and follow-up of GIOP, according to current guidelines. Clinical, laboratory and instrumental
examination results from more than 1000 patients in the first three years of the project are
planned to be documented in a prospective database.